TTI-0102: cysteamine-pantetheine disulfide

Phase 2Small molecule

TTI-0102: cysteamine-pantetheine disulfide is one of 2 small molecule programs targeting Leigh syndrome. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Leigh SyndromeNot yet recruiting

Leigh SyndromePhase 2

Not yet recruiting

Competition

Competitive Landscape

1 competitor in Leigh Syndrome

#DrugCompanyPhaseTrials

Rapamune

PPrism Pharmaceuticals

Phase 2

1 2

TTI-0102: cysteamine-pantetheine disulfide

TThiogenesis Therapeutics, Inc.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Not yet recruiting

Leigh Syndrome

NCT06990984

Clinical

Trials by Indication[1]

Leigh syndrome1 trial

A Phase 2a Partially Randomized, Placebo-controlled, Sequential Dose-ranging Study of TTI-0102 in Adults and Children With Leigh Syndrome Spectrum

Not yet recruiting·TThiogenesis Therapeutics, Inc.·Phase 2·NCT06990984·18 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for TTI-0102: cysteamine-pantetheine disulfide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TTI-0102: cysteamine-pantetheine disulfide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TTI-0102: cysteamine-pantetheine disulfide. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Thiogenesis Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: TThiogenesis Therapeutics, Inc.

TTI-0102: cysteamine-pantetheine disulfide

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Leigh syndrome1 trial

References

Drug Info

Quick Facts

Related News